logical failure, up to 30%, in populations on first-line ART, and rapid development of HIVDR [5, 6] . Low adherence to treatment, inadequate virological monitoring and other program-related factors such as drug stock-outs are associated with virological failure and the emergence and accumulation of resistance mutations [7] . In addition, as mentioned by Chimukangara and colleagues "long delays in switching people with virological failure to second-line regimens" increase the probability of transmitting a resistant virus.
As ART coverage in RLCs expands, detecting, combating, and preventing HIVDR and especially PDR, must necessarily become a growing priority. The routine monitoring of viral load (VL) is expected to improve ART outcome and should also support prevention of HIVDR [8] . In addition, VL monitoring is cost-effective, by preventing premature introduction of more costly second-line regimens, and also by reducing the need of drug resistance testing for second-line ART initiation. Therefore, strengthening the routine use of VL monitoring in RLC is essential. However, as mentioned by Chimukangara and colleagues, SA already has an effective VL monitoring program, which begs the question of what other factors may need to be considered to limit HIVDR?
The use of drugs with a low genetic barrier to resistance, especially the NNRTIs drugs such as nevirapine and efavirenz, is associated with selection and transmission of NNRTI-resistant viruses. Since 2017, the WHO has recommended non-NNRTI first-line ART regimens in countries where NNRTI PDR exceeds 10% [9] . The study from Chimukangara and colleagues supports this recommendation in SA. Also, as we now know that NNRTI PDR inevitably increases in programs using NNRTIs and represents a serious risk for ART outcome, NNRTI-free regimens should be considered in all RLCs. The WHO recommends transition to a dolutegravir (DTG)-based first-line regimen when safe for the patient, but that is not enough. In fact, Chimukangara and colleagues work also highlight the increase of NRTI PDR, especially TDF-associated resistance, which is consistent with recent studies from RLC [10] . A reasonable expectation is that TDF resistance will soon represent a serious threat and a similar scenario cannot be excluded for DTG, even though its barrier to resistance is higher.
Major limitations of the study include the fact that the true ARV status of participants is uncertain, and previous exposure to ARV for some of the study participants cannot be excluded. Also, it is essential to assess PDR in other populations, especially pediatric populations.
In conclusion, combined with similar data from RLCs, the study by Chimukangara and colleagues points to a growing threat of HIVDR and 
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